Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

JIA Wei, MDPhD, Min Xiao, Zekai Mao, Na Wang, MD PhD, Chunrui Li, MDPhD, Yang Cao, Weimin Sun, Yi Xiao, Chaojiang Gu, Shangkun Zhang, PhD, Yicheng Zhang, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD, Liang Huang, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-138947

Published: 2020

Journal Articles

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Yang Cao, Yi Xiao, Na Wang, MD PhD, Gaoxiang Wang, MDPhD, Xiaoxi Zhou, MDPhD, Liang Huang, MD, Liting Chen, PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, Jianfeng Zhou, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-140308

Published: 2020

Journal Articles

Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma

Jiang Yujie, MD, Na Wang, MD, Dai Yuan, MD, Huiting Qu, MD, Lili Feng, MD PhD, Juan Fan, MD, Xin Wang, MD PhD

Blood (2018) 132 (Supplement 1): 5343.

https://doi.org/10.1182/blood-2018-99-117608

Published: 2018

Journal Articles

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Liang Huang, MDPhD, Na Wang, MD PhD, Yang Cao, Chunrui Li, MDPhD, Yi Xiao, MD PhD, Min Xiao, MD PhD, Xiaoxi Zhou, MD, PhD, Gaoxiang Wang, MDPhD, Zhenya Hong, MD, PhD, Miao Zhen, MD, PhD, Weixu Meng, MD PhD, Bin Zhang, PhD, Yicheng Zhang, MDPhD, Guido Marcucci, Tongcun Zhang, PhD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 1408.

https://doi.org/10.1182/blood-2018-99-113714

Published: 2018

Journal Articles

Heterogeneous Responses Among Ph + -B-ALLs to Imatinib with NRAS Mutant Being One Mechanism of Complete Resistance

Xiaoyu An, Jinping Liu, Na Wang, MD PhD, Di Wang, MD PhD, Liang Huang, MD PhD, Jie Cai, PhD, Demin Zhou, PhD, Henry Li, PhD

Blood (2018) 132 (Supplement 1): 5801.

https://doi.org/10.1182/blood-2018-99-115516

Published: 2018

Journal Articles

Medium-Dose VP-16 Intensified Conditioning Regimen Is Effective in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Feifei Sun, Xiaosheng Fang, PhD, Jiang Yujie, MD, Xiaohui Sui, Xin Liu, Xianghua Wang, Ying Li, Na Wang, MD, Changqing Zhen, Huiting Qu, MD, Juan Fan, MD, Hongzhi Xu, Xin Wang, MD PhD

Blood (2018) 132 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2018-99-117825

Published: 2018

Journal Articles

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Yang Cao, Na Wang, MD PhD, Gaoxiang Wang, MD PhD, Yi Xiao, MD PhD, Liang Huang, MD PhD, Chunrui Li, MD PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, MD PhD, Jianfeng Zhou, MD PhD

Blood (2018) 132 (Supplement 1): 2054.

https://doi.org/10.1182/blood-2018-99-113827

Published: 2018

Journal Articles

Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for CD30 + Relapsed/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

Di Wang, MD PhD, Yi Xiao, MD PhD, Chunrui Li, MDPhD, Na Wang, MD PhD, Liang Huang, MDPhD, Yicheng Zhang, MDPhD, Tongcun Zhang, PhD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2018-99-116741

Published: 2018

Journal Articles

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia

Liang Huang, MD PhD, Na Wang, MD PhD, Chunrui Li, MD PhD, Yang Cao, MD PhD, Yi Xiao, MD PhD, Min Xiao, MD PhD, Yicheng Zhang, MD PhD, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD

Blood (2017) 130 (Supplement 1): 846.

https://doi.org/10.1182/blood.V130.Suppl_1.846.846

Published: 2017

Journal Articles

Clinical Subtypes, Molecular Features and Treatment Strategies of Aggressive NK-Cell Leukemia: A Multicenter Analysis of 113 Patients

Liang Huang, MDPhD, Yuting Tang, MD, Di Wang, MD PhD, Hui Luo, MD, Min Xiao, MD PhD, Dan Liu, Na Wang, MD PhD, Jianfeng Zhou, MD PhD, Qianfei Wang, PhD

Blood (2017) 130 (Supplement 1): 2796.

https://doi.org/10.1182/blood.V130.Suppl_1.2796.2796

Published: 2017

NARROW

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Heterogeneous Responses Among Ph + -B-ALLs to Imatinib with NRAS Mutant Being One Mechanism of Complete Resistance

Medium-Dose VP-16 Intensified Conditioning Regimen Is Effective in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for CD30 + Relapsed/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia

Clinical Subtypes, Molecular Features and Treatment Strategies of Aggressive NK-Cell Leukemia: A Multicenter Analysis of 113 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only